JP7393774B2 - Ｈｅｒ２標的化剤 - Google Patents

Ｈｅｒ２標的化剤 Download PDF

Info

Publication number
JP7393774B2
JP7393774B2 JP2022565479A JP2022565479A JP7393774B2 JP 7393774 B2 JP7393774 B2 JP 7393774B2 JP 2022565479 A JP2022565479 A JP 2022565479A JP 2022565479 A JP2022565479 A JP 2022565479A JP 7393774 B2 JP7393774 B2 JP 7393774B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
seq
acid sequence
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022565479A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022114163A5 (https=
JPWO2022114163A1 (https=
Inventor
幸成 加藤
美華 金子
大介 中山
雅礼 黒木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Ono Pharmaceutical Co Ltd
Original Assignee
Tohoku University NUC
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, Ono Pharmaceutical Co Ltd filed Critical Tohoku University NUC
Publication of JPWO2022114163A1 publication Critical patent/JPWO2022114163A1/ja
Publication of JPWO2022114163A5 publication Critical patent/JPWO2022114163A5/ja
Priority to JP2023195187A priority Critical patent/JP2024020436A/ja
Application granted granted Critical
Publication of JP7393774B2 publication Critical patent/JP7393774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022565479A 2020-11-30 2021-11-29 Ｈｅｒ２標的化剤 Active JP7393774B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023195187A JP2024020436A (ja) 2020-11-30 2023-11-16 Ｈｅｒ２標的化剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020198044 2020-11-30
JP2020198044 2020-11-30
JP2021110912 2021-07-02
JP2021110912 2021-07-02
PCT/JP2021/043538 WO2022114163A1 (ja) 2020-11-30 2021-11-29 Ｈｅｒ２標的化剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023195187A Division JP2024020436A (ja) 2020-11-30 2023-11-16 Ｈｅｒ２標的化剤

Publications (3)

Publication Number Publication Date
JPWO2022114163A1 JPWO2022114163A1 (https=) 2022-06-02
JPWO2022114163A5 JPWO2022114163A5 (https=) 2023-07-25
JP7393774B2 true JP7393774B2 (ja) 2023-12-07

Family

ID=81754499

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022565479A Active JP7393774B2 (ja) 2020-11-30 2021-11-29 Ｈｅｒ２標的化剤
JP2023195187A Pending JP2024020436A (ja) 2020-11-30 2023-11-16 Ｈｅｒ２標的化剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023195187A Pending JP2024020436A (ja) 2020-11-30 2023-11-16 Ｈｅｒ２標的化剤

Country Status (10)

Country Link
US (2) US20240002531A1 (https=)
EP (1) EP4253420A4 (https=)
JP (2) JP7393774B2 (https=)
KR (1) KR20230114747A (https=)
AU (1) AU2021387127A1 (https=)
CA (1) CA3199473A1 (https=)
IL (1) IL303154A (https=)
MX (1) MX2023005864A (https=)
TW (2) TW202546008A (https=)
WO (1) WO2022114163A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3247010A1 (en) 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
EP4504914A4 (en) * 2022-04-08 2026-04-29 Fate Therapeutics Inc Cells having solid tumor targeting backbone and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121943A (ja) 2009-12-07 2011-06-23 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats Ｈｅｒ２末端切断型変異体ｃｔｆ−６１１に対する抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US11851479B2 (en) * 2018-06-18 2023-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis
CA3247010A1 (en) * 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121943A (ja) 2009-12-07 2011-06-23 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats Ｈｅｒ２末端切断型変異体ｃｔｆ−６１１に対する抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRONE, A. S. et al.，Nature Medicine，2002年，Volume 8, Number 5，p. 459-465
KANEKO, Mika et al.，Biochemistry and Biophysics Reports，2020年10月10日，Volume 24, 100826
KATO, Yukinari et al.，Scientific Reports，2014年，Volume 4, 5924
YAMADA, Shinji et al.，MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY，2017年，Volume 36, Number 6，p. 287-290

Also Published As

Publication number Publication date
IL303154A (en) 2023-07-01
MX2023005864A (es) 2023-06-05
EP4253420A1 (en) 2023-10-04
TW202546008A (zh) 2025-12-01
WO2022114163A1 (ja) 2022-06-02
KR20230114747A (ko) 2023-08-01
US11981747B1 (en) 2024-05-14
US20240002531A1 (en) 2024-01-04
TW202229359A (zh) 2022-08-01
AU2021387127A1 (en) 2023-06-22
JP2024020436A (ja) 2024-02-14
JPWO2022114163A1 (https=) 2022-06-02
CA3199473A1 (en) 2022-06-02
EP4253420A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
KR101854443B1 (ko) 항-her2 항체 및 이의 접합체
CN119350498A (zh) 一种抗体及其用途
WO2016171242A1 (ja) Ｅｐｈａ２の検出
KR102029248B1 (ko) 암세포 특이적 항체, 항암제 및 암 검사 방법
US20160280793A1 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US20230365676A1 (en) Cd33 antibodies
JP2024020436A (ja) Ｈｅｒ２標的化剤
CN115505043A (zh) 特异性结合糖基化ceacam5的抗体
KR102249981B1 (ko) 단클론성 항-gpc-1 항체 및 이의 용도
JP2023544140A (ja) 新規の抗クローディン１８抗体
CA3113306A1 (en) Her2-binding tetrameric polypeptides
WO2018181656A1 (ja) 抗ｇｐｒ２０抗体
TW202309099A (zh) 結合於ｈｅｇ１蛋白質之人源化抗體
US20210395396A1 (en) Her2-binding tetrameric polypeptides
CN116615239A (zh) Her2靶向剂
US20250019432A1 (en) Cell-binding proteins and methods of use
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
HK40091222A (zh) Her2靶向剂
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
WO2025117639A9 (en) Antibodies and methods for ptk7 detection
EP4493595A1 (en) Antibodies against lypd3
CN120271715A (zh) 抗体及其药物偶联物和用途
JP2020007315A (ja) モノクローナル抗ｇｐｃ−１抗体およびその使用

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230329

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230706

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231116

R150 Certificate of patent or registration of utility model

Ref document number: 7393774

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150